Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation

NCT04173533 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT04173533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04173533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation
Lead sponsor
University of Birmingham
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2019
Completion date
April 29, 2026
Enrollment
326 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplasia